[1] Wang H, Yin S. Natural killer T cells in liver injury, inflammation and cancer. Expert Rev Gastroenterol Hepatol, 2015, 9:1077-1085.
[2] Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol, 2013, 13:101-117.
[3] Rossjohn J, Pellicci DG, Patel O, et al. Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol, 2012, 12:845-857.
[4] Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol, 2011, 11:131-142.
[5] Velazquez P, Cameron TO, Kinjo Y, et al. Cutting edge: activation by innate cytokines or microbial antigens can cause arrest of natural killer T cell patrolling of liver sinusoids. J Immunol, 2008, 180:2024-2028.
[6] Zeissig S, Murata K, Sweet L, et al. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med, 2012, 18:1060-1068.
[7] Wang H, Feng D, Park O, et al. Invariant NKT cell activation induces neutrophil accumulation and hepatitis: opposite regulation by IL-4 and IFN-gamma. Hepatology, 2013, 58:1474-1485.
[8] Martin-Murphy BV, Kominsky DJ, Orlicky DJ, et al. Increased susceptibility of natural killer T-cell-deficient mice to acetaminophen-induced liver injury. Hepatology, 2013, 57:1575-1584.
[9] Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev, 2010, 90:1165-1194.
[10] Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol, 2013, 14:996-1006.
[11] Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res, 2011, 343:43-55.
[12] Duwaerts CC, Gregory SH. Targeting the diverse immunological functions expressed by hepatic NKT cells. Expert Opin Ther Targets, 2011, 15:973-988.
[13] Wondimu Z, Santodomingo-Garzon T, Le T, et al. Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am J Pathol, 2010, 177:2334-2346.
[14] Huang M, Sun R, Wei H, et al. Simultaneous knockdown of multiple ligands of innate receptor NKG2D prevents natural killer cell-mediated fulminant hepatitis in mice. Hepatology, 2013, 57:277-288.
[15] Hosoya S, Ikejima K, Takeda K, et al. Innate immune responses involving natural killer and natural killer T cells promote liver regeneration after partial hepatectomy in mice. Am J Physiol Gastrointest Liver Physiol, 2013, 304:G293-299.
[16] Syn WK, Agboola KM, Swiderska M, et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut, 2012, 61:1323-1329.
[17] Cui K, Yan G, Xu C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1beta in mice. J Hepatol, 2015, 62:1311-1318.
[18] Maricic I, Sheng H, Marrero I, et al. Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice. Hepatology, 2015, 61:1357-1369.
[19] Tripathy AS, Das R, Chadha MS, et al. Epidemic of hepatitis B with high mortality in India: association of fulminant disease with lack of CCL4 and natural killer T cells. J Viral Hepat, 2011, 18:e415-422.
[20] Li J, Han Y, Jin K, et al. Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection. Virol J, 2011, 8:199.
[21] Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut, 2015, 64:830-841.
[22] Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol, 2013, 3:1473-1492.
[23] Gao B, Radaeva S. Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta, 2013, 1832:1061-1069.
[24] Ishikawa S, Ikejima K, Yamagata H, et al. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol, 2011, 54:1195-1204.
[25] Muhanna N, Abu Tair L, Doron S, et al. Amelioration of hepatic fibrosis by NK cell activation. Gut, 2011, 60:90-98.
[26] Mitra A, Satelli A, Yan J, et al. IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice. Hepatology, 2014, 60:2027-2039.
[27] Wehr A, Baeck C, Heymann F, et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol, 2013, 190:5226-5236.
[28] Vivier E, Ugolini S, Blaise D, et al. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol, 2012, 12:239-252.
[29] Terabe M, Berzofsky JA. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunol Immunother, 2014, 63:199-213.
[30] Schneiders FL, de Bruin RC, van den Eertwegh AJ, et al. Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up. J Clin Oncol, 2012, 30:567-570.
[31] Altman JB, Benavides AD, Das R, et al. Antitumor responses of invariant natural killer T cells. J Immunol Res, 2015, 2015:652875.
[32] Tatsumi T, Takehara T, Yamaguchi S, et al. Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor. Hepatology, 2007, 45:22-30.
[33] Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest, 2012, 122:586-599.
[34] Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell, 2014, 26:549-564.
[35] Hayakawa Y, Takeda K, Yagita H, et al. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol, 2001, 166:6012-6018. |
